^
    10d
    Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial (clinicaltrials.gov)
    P2, N=12, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: Oct 2026 --> Oct 2025
    Trial primary completion date • Tumor mutational burden
    |
    SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1)
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    13d
    An evolutionary T119R substitution in the macaque T-cell immunoreceptor TIGIT enables proteolytic shedding and reveals clinical antibody vulnerabilities. (PubMed, J Biol Chem)
    In addition, the shed ectodomain of TIGIT maintains binding to CD155 and the tested clinical anti-TIGIT antibody, tiragolumab. Given the significant anti-TIGIT failures, these unexpected findings reveal potential saturation vulnerabilities of macaque CD155 and preclinical TIGIT antibodies by soluble shedded TIGIT ectodomain, contrary to the intended mechanism of action on the lymphocyte membrane. These results caution against extrapolation and question the suitability of cynomolgus and rhesus macaques for preclinical safety and dose estimation of TIGIT-targeted therapies.
    Journal
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • PVR (PVR Cell Adhesion Molecule)
    |
    tiragolumab (RG6058)
    22d
    Imbrave 152: A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152) (clinicaltrials.gov)
    P3, N=687, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Sep 2026 --> May 2025
    Trial primary completion date
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • tiragolumab (RG6058)
    22d
    GEMINI-Hepatobiliary: Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (clinicaltrials.gov)
    P2, N=294, Recruiting, AstraZeneca | Trial completion date: Dec 2026 --> Oct 2027 | Trial primary completion date: Dec 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • cisplatin • gemcitabine • Lenvima (lenvatinib) • rilvegostomig (AZD2936) • volrustomig (MEDI5752)
    22d
    A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=199, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Oct 2025 --> Jul 2026 | Trial primary completion date: Oct 2025 --> Jul 2026
    Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    Keytruda (pembrolizumab) • Inlyta (axitinib) • tiragolumab (RG6058) • tobemstomig (RG6139)
    30d
    Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, Washington University School of Medicine | Trial completion date: Dec 2029 --> Jun 2030 | Trial primary completion date: Oct 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Yutuo (zimberelimab) • domvanalimab (AB154) • etrumadenant (AB928)
    1m
    SKYSCRAPER-11: A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Sep 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    VENTANA PD-L1 (SP263) Assay
    1m
    STAR-221: A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (clinicaltrials.gov)
    P3, N=1040, Active, not recruiting, Arcus Biosciences, Inc. | Trial completion date: Feb 2027 --> Jun 2026 | Trial primary completion date: Dec 2026 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • Yutuo (zimberelimab) • leucovorin calcium • domvanalimab (AB154)
    1m
    A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer (clinicaltrials.gov)
    P2, N=204, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Dec 2026 --> Mar 2026 | Trial primary completion date: Dec 2026 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
    1m
    SKYSCRAPER-08: A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma (clinicaltrials.gov)
    P3, N=461, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Aug 2025
    Trial completion • Trial completion date
    |
    cisplatin • Tecentriq (atezolizumab) • paclitaxel • tiragolumab (RG6058)
    1m
    AB02: A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) (clinicaltrials.gov)
    P3, N=1100, Not yet recruiting, AstraZeneca
    New P3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • rilvegostomig (AZD2936)
    1m
    ASP8374 + Cemiplimab in Recurrent Glioma (clinicaltrials.gov)
    P1, N=14, Completed, Dana-Farber Cancer Institute | Active, not recruiting --> Completed
    Trial completion
    |
    Libtayo (cemiplimab-rwlc) • ASP8374